Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With Small Cell Neuroendocrine Prostate Cancer

Trial Profile

Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With Small Cell Neuroendocrine Prostate Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Talabostat (Primary)
  • Indications Adenocarcinoma; Neuroendocrine carcinoma; Prostate cancer
  • Focus First in man; Therapeutic Use
  • Sponsors BioXcel Therapeutics
  • Most Recent Events

    • 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 28 Apr 2020 According to a BioXcel Therapeutics media release, in the phase II efficacy portion of the trial, approximately 30 patients will receive 0.3 mg of BXCL701 twice daily (BID) on days 1 through 14 of a 21-day cycle plus 200 mg of pembrolizumab administered intravenously on day 1 and every subsequent 21 days.
    • 28 Apr 2020 Results from the Phase 1b safety assessment, presented in a BioXcel Therapeutics media release.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top